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ABSTRACT
In the present study, we dissected the pathways that
trigger the IL-17A responses by MTB. Dectin-1 and TLR4
were shown to be involved in MTB-induced IL-17A pro-
duction, and blockade of the NOD2, TLR2, or MR had no
effect on IL-17A. The MAPK Erk, known to mediate tran-
scription of IL-1mRNA, was strongly involved in the IL-
17A production induced by MTB. The intracellular en-
zymes caspase-1 and serine proteases, which process
pro-IL-1 into the active IL-1, were also crucial for the in-
duction of IL-17A. Lastly, the MTB-induced IL-17A re-
sponse was strongly dependent on signaling through the
IL-1R but not the IL-6R pathway. In conclusion, the MTB-
induced IL-17A response relies strongly on the endoge-
nous IL-1 pathway and IL-1R signaling. TLR4 and dectin-1
are the main receptors responsible for mediating the sig-
nals responsible for IL-17A production by MTB. These
findings contribute to a better understanding of the
host response to mycobacteria and provide the op-
portunity to explore potential, novel, therapeutic
strategies against TB. J. Leukoc. Biol. 88: 227–232;
2010.
Introduction
TB remains an important public health problem with 2 million
deaths per year [1]. Although several mechanisms of MTB im-
mune control have been elucidated, there remains a critical need
to better understand the host defense mechanisms leading to
elimination of the pathogen, latent disease, or active TB [2, 3].
Recently, a distinct IL-17A-producing subset of memory CD4 T
cells (Th17 cells) with specificity for MTB has been described,
and it has been suggested that they have an important contribu-
tion to the human antimycobacterial immune response [4].
In addition, novel vaccination strategies have focused on induc-
ing TB-specific Th17 responses, as the IL-17A pathway induced
after immunization has been shown to contribute to the protec-
tion at the site of infection [5]. In this respect, IL-17A does not
appear to play a major role in primary TB infection but seems
mainly to be involved in the maintenance of the inflammatory
response. In line with this, granuloma formation in the lungs of
IL-17A-deficient mice infected with BCG was reported to be im-
paired [6], and IL-17A was shown to play a role in the trafficking
of Th1 cells to the site of infection [7]. These data strongly un-
derline the importance of the IL-17A response in host defense
against TB and provide the rationale for developing vaccines that
induce a strong TB-specific Th17 response.
Although many studies have focused on the importance of IL-
17A in antimycobacterial host defense, little is known about the
mechanisms through which MTB triggers the Th17-specific host
response. The induction of Th17 responses by microorganisms
has been reported to be induced by several TLRs, NLRs, and C-
type lectin receptors. The main receptors reported for inducing a
pathogen-specific Th17 response are TLR2, TLR4, NOD2, dec-
tin-1, and MR [8–11]. Interestingly, recognition of MTB has been
associated with recognition by these receptors, but which of them
are responsible for the MTB-induced IL-17A responses is not yet
known [12–18]. Regarding the cytokines that play a role in the
induction of Th17 responses, IL-1 and IL-6 have been impli-
cated as the main Th17-polarizing cytokines for memory CD4 T
cells in humans [19]. Recently, it has been shown that IL-1 signal-
ing is crucial for the early development of Th17 cells [20]. In the
present study, we have focused on the induction of IL-17A by
MTB and tried to identify the mechanisms involved in triggering
the IL-17A response by MTB.
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MATERIALS AND METHODS
Volunteers
Blood was collected after informed consent by venipuncture into 10 ml EDTA
syringes (Monoject) from seven healthy volunteers. None of the volunteers
had a history of a positive tuberculin skin test or was vaccinated with BCG. Five
patients with Crohn’s disease with 3020insC mutation, without immunosuppressive
medication, were investigated further in the cytokine studies. The Ethics Commit-
tee of Radboud University Nijmegen (The Netherlands) approved the study.
Animals
Balb/c control mice (Charles River Wiga, Sulzfeld, Germany) and DPPI-defi-
cient mice (Balb/c background; Christine T. Pham), 10–14 weeks, were bred
and housed (Radboud University Nijmegen Medical Centre) in filter-top
cages, and water and food were supplied ad libitum. The Radboud University
Animal Ethical Committee approved all animal experiments.
MTB
MTB H37Rv was grown to mid-log phase in Middlebrook 7H9 liquid medium
supplemented with oleic acid/albumin/dextrose/catalase (Difco, Becton Dick-
inson, Palo Alto, CA, USA), heat-killed at 100°C for 1 h, washed three times in
sterile saline, and resuspended in RPMI 1640.
In vitro cytokine production
Separation and stimulation of PBMCs were performed as described pre-
viously [21]. PBMCs (5105) in a volume of 200 l/well were incubated
at 37°C in round-bottom 96-wells plates (Greiner, Nuremberg, Ger-
many) with 10% human pooled serum. In blocking experiments, PBMCs
were stimulated with heat-killed MTB (110e5 microorganisms/ml) in
the absence or presence of inhibitors [preincubation 1 h: anti-TLR4 in-
hibitor Bartonella quintana LPS 100 ng/ml; mannose 100 nM (Sigma
Chemical Co., St. Louis, MO, USA); anti-TLR2 10 g/ml and control
anti-IgA 10 g/ml (InvivoGen, San Diego, CA, USA); laminarin 10
g/ml (Dr. David Williams, University of Tennessee, Knoxville, TN,
USA); IL-1RA 10 g/ml (Prof. Charles Dinarello, University of Colo-
rado, Boulder, CO, USA); 10 g/ml humanized IL-6R antibody tocili-
zumab (Roche Nederland BV, The Netherlands); and 20 nM SB202190
(p38-i), SP600125 (JNK-i), and 10 nM U0126 (Erk-i; Superarray Bio-
science, Bethesda, MD, USA); no preincubation: caspase-1 inhibitor Tyr-
Val-Ala-Asp (Alexis Biochemicals, San Diego, CA, USA); protease inhibi-
tor 2 macroglobulin (Sigma Chemical Co.); and equivalent concentra-
tion of vehicle (0.01–0.1% DMSO) where appropriate]. Viability of the
cells was not affected by the MAPK inhibitors, as shown by unaffected
lactate dehydrogenase measurements in the supernantants of cells incu-
bated with the various inhibitors (not shown). Mouse spleen cells (1
mL), resuspended in RPMI 1640, adjusted to 5  106 mL1, were stimu-
lated for 48 h with heat-killed MTB.
Cytokine assays
Cytokines were measured by commercial ELISA kits according to the instruc-
tions of the manufacturer. Human IL-1, IL-6, IL-17A, and IL-22 and mouse
IL-17A concentrations (R&D Systems, Minneapolis, MN, USA) and IFN- (Bio-
Figure 1 . MTB induces IL-17A response in human PBMCs. (A and B) Hu-
man PBMCs were stimulated for 7 days with RPMI or different concentrations
of heat-killed MTB/ml. (C and D) Intracellular cytokine staining of IL-17 and
IFN- in human PBMCs stimulated for 7 days with RPMI or heat-killed MTB
and then stimulated for 4 h with PMA and ionomycin. Cells were gated for
(C) CD4 and (D)  T cells, and data are given as percent of total gated, posi-
tive cells. (A and B) IL-17A, IL-22, IL-1, and IL-6 were measured by ELISA.
Data are pooled and expressed as mean  sem; n  4 volunteers. (C and D)
Data from one healthy volunteer, which represent the pattern observed in two
separate experiments with a total of n  3 volunteers.
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source, Camarillo, CA, USA) were measured by commercial ELISA kits accord-
ing to the instructions of the manufacturer.
Intracellular cytokine staining
Four hours before the staining, the supernatant was aspirated, and culture me-
dium with brefeldin A (10 g/ml), PMA (0.05 g/ml), and ionomycin (1 g/
ml) was added. Cells were stained with live/dead fixable dead cell stain kits
Aqua (Invitrogen, Carlsbad, CA, USA) for 30 min on 4ºC, washed with PBS
containing 0.5% albumin for bovine serum (Sigma Chemical Co.), and stained
with IOTest anti-TCR Pan /-PE (Beckman-Coulter, Fullerton, CA, USA),
IOTest CD45RO-phycoerythrin Texas Red (Beckman-Coulter), PerCP anti-human
CD3 (BioLegend, San Diego, CA, USA), PE-Cy7 anti-human CD45RA (eBio-
science, San Diego, CA, USA), and Pacific Blue anti-human CD4 (eBioscience)
for 20 min on 4ºC. After washing, cells were incubated with fixation Medium
A (Caltag, S. San Francisco, CA, USA) and subsequently, incubated with FITC
anti-human IFN- (eBioscience) and Alexa Fluor 647 anti-human IL-17A (BD
PharMingen, San Diego, CA, USA) in permeabilization Medium B (Caltag) for
20 min on 4ºC. Cells (100,000) gated on a lymphocyte gate by forward- and
side-scatter were acquired on a CyAn ADP 9 color flow cytometer (Beckman-
Coulter). Data were analyzed using the FlowJo software program.
Statistical analysis
Differences between groups were analyzed by a two-tailed paired t-test or the
Mann-Whitney U test. Differences were considered statistically significant when
P  0.05. All experiments were performed at least twice, and the data are pre-
sented as the cumulative result of all experiments performed.
RESULTS AND DISCUSSION
Th17 cells, characterized by the production of IL-17A, IL-
17AF, IL-21, and IL-22, contribute to the human antimycobac-
terial immune response [4]. In line with this, we were able to
demonstrate that MTB induces IL-17A and IL-22 production
in a dose-dependent manner (Fig. 1A). In addition, produc-
tion of the proinflammatory cytokines IL-1 and IL-6, which
are involved in driving CD4-positive memory T cells toward
Th17 cells, was also induced by MTB (Fig. 1B). It has been
reported that the main cellular source of MTB-induced IL-17A
production in human PBMCs was a subset of CD4 T cells
(Fig. 1C) [4, 22]. In the present study, we show that there is
an increase in double IL-17A/IFN--positive CD4 memory T
cells after stimulation with MTB in vitro; CD4 naı¨ve T cells
did not express IL-17A (Fig. 1C). These data support the con-
cept that in humans, the CD4 memory T cells are the main
source responsible for IL-17A production during infection
with MTB. However, the presence of CD4 memory T cells
responding with IL-17A release upon stimulation with MTB in
individuals who have a negative purpose of tuberculin skin test
and have not been vaccinated with BCG is likely to mirror the
presence of a nonspecific, primed subset of memory Th cells,
which is able to express IL-17 after MTB exposure. We are cur-
rently investigating this important observation. In addition,
animal models have provided evidence that T cells rather
than CD4 memory T cells are the main source for IL-17A
production induced by MTB [23], and T cells have been
recognized as an important innate source of IL-17A produc-
tion [24, 25]. Interestingly, IL-17A was also expressed in a
small subpopulation of T cells after stimulation with MTB
(Fig. 1D), indicating that T cells contribute to IL-17A pro-
duction during MTB infection in humans. It remains to be
elucidated which subset is predominantly responsible for the
observed IL-17A production after a MTB infection.
The recognition of MTB is mediated by a complex net-
work of TLRs (among which include TLR2 and TLR4), lec-
tin receptors (dectin-1 and MR), and the NLR receptor
NOD2 [12–18]. We assessed which of the various PRRs are
involved in the induction of IL-17A by MTB. Dectin-1 block-
ade led to inhibition of mycobacteria-induced IL-17A
(Fig. 2A), which is in line with the fact that dectin-1 has
been recognized as one of the main receptors that skews Th
responses toward a more Th17 profile [26]. Notably, the
Syk-caspase recruitment domain-containing protein 9 path-
way through which dectin-1 signals has been suggested re-
cently as a rational target for vaccine development against
Figure 2. IL-17A induced by MTB is dependent on TLR4 and dectin-1
but independent of NOD2 and MR. Human PBMCs were stimulated
for 7 days with 10e5 heat-killed MTB/ml in the presence or absence
of (A) dectin-1 inhibitor 50 g/ml, (B) mannose 100 nM (C; n6 vol-
unteers), (D) TLRA inhibitor 20 ng/ml [B, quintana LPS (Bart LPS)].
(C) Human PBMCs from five patients with NOD2 deficiency were
stimulated for 7 days with 10e5 heat-killed MTB/ml and compared
with healthy volunteers (n9); wt, wild-type. IL-17A was measured by
ELISA. Data are pooled and expressed as mean  sem; *, P  0.05.
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TB, as it is critical for inducing a robust Th17 response to a
MTB subunit vaccine [5].
The MR is involved in the recognition of Man-LAM of myco-
bacteria [27] and can mediate phagocytosis of mycobacteria
[28]. Furthermore, the MR has been reported to be the main
pathway involved in the induction of IL-17A by Candida albi-
cans [11]. However, there was no significant difference in IL-
17A production when MR was blocked by high concentrations
of mannose. This observation is supported by the recent evi-
dence that the Man-LAM does not dominate the mycobacteria-
host interaction [29].
NOD2 has been suggested to be able to induce Th17 re-
sponses [10], and it can mediate recognition of mycobacteria
[17]. Interestingly, PBMC from individuals defective in NOD2
function (Crohn’s disease patients homozygous for the
3020insC NOD2 mutation) [30], stimulated with MTB, re-
leased the same amounts of IL-17A as healthy volunteers (Fig.
2C), making it unlikely that NOD2 plays an important role in
the induction of the Th17 response induced by MTB.
It is generally accepted that TLR2 is one of the main recep-
tors that recognizes MTB [31]. A commercial antibody de-
scribed to antagonize TLR2 had no effect on MTB-induced
IL-17A production (not shown). However, the inhibitory pro-
file on the cytokine production induced by the specific TLR2
ligand tripalmitoyl-S-glyceryl cysteine revealed only 30–40%
inhibition using this antibody, which precludes us to draw de-
finitive conclusions about the role of TLR2 for the induction
of IL-17A by MTB. On the other hand, the same approach has
clearly demonstrated TLR2 involvement in the IL-17A stimula-
tion by C. albicans [11], which suggests that the lack of effect
of TLR2 in the case of MTB is genuine.
Less anticipated was the observed role for TLR4 in the
MTB-induced IL-17A response. When TLR4 was blocked, a
significant reduction in IL-17A production was observed (Fig.
2D). TLR4 recognizes a heat-labile component from MTB
[32], and one study has reported the potency of TLR4-medi-
ated signals to induce Th17 responses [8]. As IL-17A has been
suggested to be involved in the maintenance of the inflamma-
tory response that provides long-lasting protection against TB,
these data suggest that TLR4 is not involved in primary TB
host defense but rather, plays a role in secondary immune re-
sponses providing protection.
TLR4 and dectin-1 most likely contribute to the IL-17A re-
sponse by inducing a specific cytokine profile that is able to
skew the Th response toward a Th17 profile. Further investiga-
tion is needed to determine whether PRRs also play a specific
role in antigen presentation during the induction of the Th17
response by MTB. Recently, Mincle has been identified as the
receptor for the mycobacterial cell wall glycolipid cord factor
(TDM) [33]. As this receptor is also expressed on T cells, it
has been suggested that T cells might recognize TDM in a
Mincle-dependent manner, which could trigger T cell activa-
tion and cytokine production directly. Whether MTB could
induce IL-17A production directly in a TCR-independent
mechanism remains to be elucidated.
The IL-1R has been shown recently to be critical for the
early development of the Th17 response [20]. Furthermore,
IL-1 and also IL-6 are suggested to be involved in the produc-
tion of IL-17A by memory T cells [19]. When PBMC were stim-
ulated with MTB, blocking the IL-6R did not affect IL-17A pro-
duction, and blocking IL-1 signaling with IL-1RA led to an al-
most complete inhibition of IL-17A (Fig. 3A). This demonstrates
that endogenous IL-1 plays a central role for the Th17 responses
induced by mycobacteria and that the processes affecting IL-1
production would be likely to have a strong influence on IL-
17A production induced by MTB. We have undertaken a sys-
Figure 3. IL-17A production induced by MTB is dependent on IL-1. Human PBMCs were stimu-
lated for 7 days with 10e5 heat-killed MTB/ml in the presence or absence of (A) IL-1RA 10
g/ml or anti-IL-6R 10 g/ml; (B) inhibitors for the kinases p38 (20 nM), Erk (10 nM), or
JNK (25 nM); (C) protease inhibitor 2 macroglobulin 10 g/ml or caspase-1 inhibitor 20 nM.
(D) Splenocytes from DPPI-deficient (n4) and wild-type mice (n4) were stimulated for 48 h
with 10e5 heat-killed MTB/ml, and concentrations of IL-17A and IFN- were measured by
ELISA. Data are pooled and expressed as mean  sem; *, P  0.05; n  4 (A and B); n  6 vol-
unteers (C). sIL-6R, Soluble IL-6R.
230 Journal of Leukocyte Biology Volume 88, August 2010 www.jleukbio.org
tematic assessment of the transcriptional and post-transcrip-
tional mechanisms known to mediate the release of bioactive
IL-1 from monocytes. Recently, it was demonstrated that the
MAPK Erk and p38 but not JNK are important for the induc-
tion of transcription of IL-1 mRNA [34]. In line with this, Erk
inhibition lowered the production of IL-1 and IL-17A in-
duced by MTB, and JNK inhibition had no effect (Fig. 3B).
Results from experiments that blocked p38 MAPK were less
clear but showed a trend toward lower IL-17A production (Fig.
3B). In addition, when blocking the enzymes responsible for
the processing of the inactive pro-IL-1 into the active IL-1,
such as caspase-1 [35] and the inflammatory serine proteases
(a family comprising protease 3, elastase, cathepsin G) [36],
IL-17A production was strongly down-regulated (Fig. 3C). In
line with this, cells from DPPI knockout mice, which are also
deficient in serine proteases, showed a strong defect in induc-
ing IL-17A (Fig. 3D). This effect was specific for the IL-17A
responses, as IFN- production was not affected (Fig. 3D). Al-
together, these data underline the central role of endogenous
IL-1 in the induction of the IL-17A response by MTB.
In the present study, we elucidate the pathways through
which MTB activates the IL-17A response. The PRRs involved
in triggering the IL-17A response are TLR4 and dectin-1 but
not NOD2, TLR2, or MR. Release of endogenous IL-1 is a cen-
tral event for the induction of the IL-17A response by MTB, as
blocking of the various steps responsible for the production
and release of IL-1 also inhibited IL-17A. These findings con-
tribute to a better understanding of the host response to my-
cobacteria and provide the opportunity to explore novel treat-
ment and vaccination strategies that could be beneficial in
fighting the global burden of TB.
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